relationship
viru
infect
host
immun
respons
complex
outcom
viru
infect
shape
interplay
variou
multilay
event
viralhost
interact
classic
virus
initi
cycl
infect
attach
viral
surfac
protein
specif
target
cell
receptor
viral
surfac
protein
extrem
immunogen
structur
bind
stimul
innat
adapt
immun
respons
sahay
et
al
neutral
antibodi
inhibit
viru
infect
bind
surfac
domain
essenti
viru
replic
receptor
bind
site
rb
fusion
peptid
taylor
et
al
circumst
viralinduc
antibodi
could
detriment
result
enhanc
ill
antibodi
depend
enhanc
ade
ade
first
report
hawk
et
al
demonstr
enhanc
infect
number
flavivirus
murray
valley
enceph
viru
west
nile
viru
wnv
japanes
enceph
viru
jev
presenc
virusspecif
antisera
specif
igg
antibodi
hawk
downstream
studi
explain
phenomenon
shown
bind
virion
nonneutr
subneutr
antibodi
could
lead
effici
viral
uptak
target
cell
receptor
taylor
et
al
complement
dependentmedi
mechan
takada
kawaoka
lead
enhanc
replic
pathogen
figur
ade
subsequ
report
wide
rang
virus
includ
flavivirus
dengu
halstead
orourk
zika
bardina
et
al
respiratori
virus
influenza
ochiai
et
al
respiratori
syncyti
viru
rsv
polack
et
al
mani
other
robinson
et
al
takada
et
al
meyer
et
al
tabl
viru
infect
vaccin
elicit
differ
type
antibodi
compos
neutral
nonneutr
enhanc
nonenhanc
antibodi
takada
et
al
viru
neutral
explain
two
model
singlehit
model
neutral
suffici
occur
bind
singl
antibodi
specif
epitop
multihit
model
neutral
requir
bind
multipl
antibodi
number
exce
neutral
stoichiometr
threshold
klass
sattentau
recent
develop
antibodi
isol
character
well
epitop
map
led
signific
progress
identifi
epitop
antibodi
respons
either
protect
diseas
enhanc
nonetheless
involv
mechan
still
fulli
understood
note
understand
ade
mechan
contribut
develop
safe
effect
vaccin
therapi
review
summar
recent
find
viral
enhanc
diseas
ill
discuss
potenti
underli
molecular
mechan
trigger
develop
disord
studi
concern
humor
respons
influenza
virus
focu
studi
protect
antibodi
respons
major
surfac
glycoprotein
hemagglutinin
ha
ramakrishnan
et
al
ha
trimer
protein
two
structur
distinct
region
stem
globular
head
wilson
et
al
success
infect
influenza
viru
requir
cleavag
ha
molecul
two
domain
carri
rb
mediat
viral
fusion
steinhauer
viru
neutral
majorli
attain
antibodi
target
ha
protein
turn
evolv
recurr
amino
acid
mutat
antigen
site
contrast
semiconserv
stem
region
remark
humor
respons
also
elicit
neuraminidas
na
prevent
viral
infect
may
contribut
effectormedi
neutral
ramakrishnan
et
al
first
studi
report
ade
context
influenza
infect
appear
use
rat
model
assess
respons
heterolog
challeng
immun
webster
askona
sinc
sever
studi
conduct
understand
ade
influenza
vitro
ochiai
et
al
found
antibodi
rabbit
previous
expos
influenza
mediat
influenza
growth
macrophag
via
entri
concentr
depend
manner
ochiai
et
al
ochiai
et
al
specif
antibodi
ha
na
protein
shown
augment
viral
uptak
antigen
present
cell
tamura
et
al
observ
elabor
anim
model
studi
use
inactiv
vaccin
two
swine
influenza
virus
immun
pig
protect
achiev
homolog
challeng
whilst
enhanc
diseas
observ
heterolog
challeng
vincent
et
al
similar
result
obtain
use
inactiv
humanlik
deltaclust
immun
pig
gauger
et
al
gauger
et
al
moreov
data
vaccin
ferret
model
show
preexist
antibodi
associ
enhanc
lung
diseas
mortal
upon
infect
unmatch
strain
kobing
et
al
anoth
studi
prior
exposur
ferret
trival
inactiv
vaccin
tvi
result
enhanc
diseas
challeng
pandem
viru
skowronski
et
al
addit
vaccin
pig
recombin
hemagglutinin
ha
subunit
elicit
high
neutral
antibodi
homolog
viru
induc
vaccineassoci
enhanc
respiratori
diseas
vaerd
heterolog
viru
challeng
et
al
also
recent
studi
matern
deriv
antibodi
caus
enhanc
respiratori
diseas
piglet
follow
heterolog
influenza
challeng
rajao
et
al
evid
influenzainduc
ade
also
report
human
observ
studi
human
show
trival
inactiv
influenza
vaccin
could
potenti
enhanc
pandem
infect
ill
skowronski
et
al
direct
contrast
recent
work
mice
evalu
observ
show
preexist
nonneutr
antibodi
administr
tiv
associ
enhanc
diseas
fact
shown
promot
antigen
present
activ
virusspecif
cell
kim
et
al
differ
observ
human
mice
could
attribut
sever
factor
includ
differ
antibodi
type
class
two
speci
titer
antibodi
blood
challeng
model
use
mice
mani
other
although
numer
studi
report
ade
due
influenza
infect
vaccin
potenti
mechan
still
well
understood
ade
classic
explain
enhanc
viru
uptak
fc
mediat
mechan
potenti
mechan
demonstr
influenza
infect
ochiai
et
al
tamura
et
al
taylor
et
al
fcindepend
mechan
also
suggest
caus
enhanc
use
structur
viral
kinet
model
shown
profusogen
stem
antibodi
would
bind
crosslink
molecul
ha
enabl
order
orient
toward
host
membran
augment
viral
fusion
effici
thu
lead
enhanc
viru
infect
ramakrishnan
et
al
anoth
studi
khurana
et
al
character
antibodi
associ
ade
pig
vaccin
whole
inactiv
humanlik
vaccin
challeng
heterolog
viru
khurana
et
al
sera
immun
pig
show
high
titer
crossreact
ha
antibodi
direct
region
head
antibodi
associ
enhanc
ill
analysi
identifi
antibodi
recogn
immunodomin
epitop
map
amino
acid
domain
studi
highlight
role
antibodi
enhanc
viral
fusion
via
fcindepend
pathway
importantli
known
exist
two
distinct
conform
form
preand
postfus
form
structur
base
analysi
reveal
residu
locat
complex
activ
complement
pathway
bind
follow
activ
protein
recruit
produc
convertas
turn
hydrolys
produc
bind
viru
complement
receptor
cr
cr
bear
cell
cell
lysi
enhanc
diseas
patholog
within
epitop
complet
hidden
prefus
conform
form
indic
enhanc
antibodi
direct
toward
postfus
conform
ramakrishnan
et
al
contrast
prefus
neutral
stem
direct
antibodi
act
inhibitor
viral
fusion
unlik
caus
ade
reveal
sever
report
demonstr
ramakrishnan
et
al
use
mathemat
model
ramakrishnan
et
al
even
absenc
measur
neutral
activ
prefus
stemdirect
antibodi
shown
confer
product
heterolog
challeng
mice
ferret
yassin
et
al
observ
respiratori
syncyti
viru
rsv
antibodi
complex
format
also
propos
lead
ade
influenza
infect
ramakrishnan
et
al
propos
mechan
nonneutr
antibodi
thought
stimul
immun
respons
result
format
immun
complex
tissu
damag
connor
et
al
howev
respiratori
infect
cell
immun
respons
influenza
strongli
bias
toward
cell
lead
product
turn
suppress
cell
wohlleben
et
al
deng
et
al
henc
modul
immun
system
toward
respons
support
mechan
ade
influenza
taken
togeth
current
avail
data
suggest
ade
influenza
strain
specif
induc
primarili
nonneutr
antibodi
nonetheless
prefus
stemdirect
antibodi
like
caus
ade
fact
ha
prefus
stemonli
vaccin
consid
promis
influenza
vaccin
induc
broad
protect
moreov
current
data
underscor
need
studi
clinic
trial
improv
understand
ade
influenza
rsv
major
caus
hospit
young
children
licens
rsv
vaccin
avail
rsv
ill
constitut
substanti
burden
health
care
servic
shi
et
al
infect
rsv
initi
two
major
surfac
glycoprotein
attach
glycoprotein
g
fusion
f
glycoprotein
target
neutral
antibodi
consid
recombin
vaccin
develop
mclellan
et
al
first
report
enhanc
rsv
diseas
publish
administr
formalininactiv
vaccin
rsv
firsv
result
high
incid
sever
ill
led
increas
hospit
among
vaccin
infant
compar
nonimmun
infant
kim
et
al
unfortun
two
vaccin
infant
also
die
enhanc
rsv
infect
kim
et
al
use
vitro
analysi
found
monoclon
antibodi
direct
two
rsv
surfac
glycoprotein
nucleoprotein
enhanc
viral
infect
macrophag
gimenez
et
al
ananaba
anderson
infect
enhanc
diminish
block
fc
part
antibodi
fc
receptor
cell
krilov
et
al
much
effort
devot
explain
mechan
rsvinduc
ade
use
anim
model
interestingli
immun
formalininactiv
rsv
result
similar
respons
anim
model
includ
monkey
ponnuraj
et
al
cotton
rat
princ
mice
wari
et
al
moreov
thelper
bia
toward
respons
detect
mice
prime
inactiv
viru
f
glycoprotein
subunit
graham
et
al
increas
level
associ
enhanc
lung
patholog
combin
deplet
deplet
cell
abrog
enhanc
pulmonari
histopatholog
induc
rsv
inactiv
vaccin
connor
et
al
connor
et
al
knudson
et
al
high
level
also
observ
macaqu
de
swart
et
al
observ
highlight
possibl
role
respons
rsvinduc
ade
patholog
mechan
underli
absenc
protect
antibodi
rsv
vaccin
remain
unexplain
long
time
wide
accept
hypothesi
attribut
lack
protect
antigen
alter
formalin
earlier
work
show
carbonyl
group
formaldehydeinactiv
rsv
boost
respons
lead
enhanc
ill
moghaddam
et
al
howev
report
show
lack
affin
matur
b
cell
follow
poor
tolllik
receptor
tlr
activ
reason
behind
elicit
nonprotect
antibodi
delgado
et
al
concept
appli
virus
measl
belong
famili
like
rsv
found
formalin
inactiv
measl
vaccin
elicit
nonprotect
low
avid
antibodi
result
atyp
sever
measl
polack
et
al
case
low
avid
antibodi
abl
neutral
viru
inhibit
bind
high
affin
measl
receptor
fact
promot
mediat
immun
led
activ
complement
format
immun
complex
turn
contribut
enhanc
patholog
delgado
et
al
acosta
et
al
consequ
affin
matur
explain
ade
develop
children
seroposit
rsv
vaccin
high
avid
antibodi
natur
develop
viral
exposur
possibl
confer
protect
outcompet
vaccineinduc
low
avid
antibodi
thu
reduc
pathogen
b
cell
prime
kim
et
al
acosta
et
al
also
explain
ade
occur
lifetim
natur
occur
viral
infect
result
activ
new
subset
b
cell
matur
produc
high
avid
antibodi
outcompet
vaccineelicit
pathogen
b
cell
acosta
et
al
would
prevent
enhanc
diseas
reinfect
restor
healthi
immun
respons
also
assum
rsv
g
protein
would
induc
ade
absenc
f
protein
howev
rsv
recombin
vaccin
encod
g
protein
induc
similar
ade
respons
inactiv
wild
type
viru
johnson
et
al
polack
moreov
found
conserv
cysteinerich
region
g
protein
antiinflammatori
respons
rsv
infect
inhibit
cytokin
product
antagon
tlr
polack
et
al
although
rsv
glycoprotein
g
f
main
target
neutral
antibodi
acosta
et
al
rsv
f
protein
conserv
display
neutral
epitop
taleb
et
al
accordingli
vaccin
f
protein
elicit
high
level
crossreact
protect
compar
g
protein
melero
moor
f
protein
either
conform
postfus
postf
prefus
pref
consid
develop
novel
vaccin
therapeut
monoclon
antibodi
melero
moor
recent
demonstr
firsv
vaccin
predominantli
present
f
protein
postfus
conform
unlik
infecti
virion
present
pref
postf
killikelli
et
al
studi
group
show
neutral
antibodi
human
sera
direct
pref
protein
immun
pref
elicit
potent
neutral
antibodi
data
partial
explain
product
nonprotect
antibodi
follow
firsv
vaccin
formalin
inactiv
alter
viru
infect
also
viru
antigen
multipl
recent
studi
focus
investig
efficaci
f
protein
either
conform
subunit
vaccin
interestingli
immun
viru
like
particl
vlp
combin
adjuv
induc
protect
immun
respons
cimica
et
al
show
immun
pref
postf
vlp
assembl
human
metapneumoviru
hmpv
matrix
protein
induc
full
protect
prevent
lung
diseas
mice
challeng
cimica
et
al
fact
combin
vaccin
contain
preand
postf
protein
induc
highest
neutral
respons
cimica
et
al
rsv
postf
subunit
vaccin
adjuv
agonist
glucopyranosyl
lipid
gla
form
stabl
emuls
se
glase
afford
robust
neutral
protect
rodent
lambert
et
al
similarli
immun
cotton
rat
recombin
f
either
pre
post
conform
adjuv
glase
elicit
high
neutral
antibodi
provid
protect
challeng
schneiderohrum
et
al
interestingli
low
vaccin
dose
mimic
wane
immun
respons
lung
patholog
observ
independ
combin
recombin
f
bias
glase
bias
alum
adjuv
schneiderohrum
et
al
result
highlight
import
evalu
rsv
vaccin
wide
dose
rang
assess
protect
ade
respons
accur
six
antigen
site
describ
f
protein
link
viral
neutral
two
v
present
exclus
pref
four
ii
iii
iv
present
variou
degre
conform
tian
et
al
specif
antigen
site
found
induc
higher
neutral
activ
epitop
mclellan
et
al
recent
studi
shown
rsv
neutral
antibodi
adult
human
direct
pref
target
site
ngwuta
et
al
highlight
import
pref
antigen
boost
induc
function
highli
potent
antibodi
respons
rsv
ngwuta
et
al
consequ
stabil
pref
consid
promis
vaccin
especi
vulner
group
includ
young
infant
pregnant
femal
immunocompromis
patient
elderli
fact
vaccin
stabil
pref
recombin
vaccin
consid
pregnant
women
third
trimest
boost
alreadi
exist
b
cell
enhanc
transfer
matern
antibodi
newli
born
infant
taleb
et
al
nonetheless
novel
efficaci
protect
vaccin
requir
care
evalu
anim
human
context
enhanc
diseas
ill
sarscov
first
appear
guangdong
provinc
china
follow
epidem
countri
affect
result
case
although
sarscov
primarili
infect
respiratori
tract
found
directli
infect
replic
human
immun
cell
despit
absenc
angiotensin
iconvert
enzym
sar
receptor
cell
li
et
al
kuba
et
al
imai
et
al
antibodymedi
cell
entri
suggest
possibl
mechan
sarscov
infect
immun
cell
taylor
et
al
accordingli
sever
studi
investig
mechan
underli
sarscov
mediat
ade
initi
report
kam
et
al
immun
recombin
fulllength
sarscov
spike
sprotein
elicit
protect
immun
respons
vivo
induc
viral
infect
human
b
cell
vitro
via
pathway
suggest
novel
ade
mechan
sarscov
kam
et
al
similarli
result
jaum
et
al
studi
show
antispik
antibodi
abl
potenti
infect
immun
cell
sarscov
spikepseudotyp
lentivir
particl
sarscovpp
replicationcompet
sarscov
likewis
antibodymedi
infect
depend
independ
jaum
et
al
anoth
studi
demonstr
enhanc
infect
replicationcompet
sarscov
well
sarscovpp
microphag
link
antispik
igg
specif
signal
yip
et
al
wang
et
al
found
ade
respons
stimul
antibodi
sarscov
spike
protein
rather
nucleoprotein
wang
et
al
also
shown
studi
ade
respons
depend
antibodi
titer
sera
high
antibodi
concentr
neutral
viru
dilut
sera
significantli
enhanc
infect
induc
apoptosi
wang
et
al
classic
follow
bind
receptor
sarscov
enter
suscept
cell
phdepend
endocytosi
yang
et
al
moreov
lysosom
cystein
proteas
cathepsin
l
found
play
crucial
role
achiev
effici
infect
huang
et
al
contrast
fcrmediat
infect
occur
independ
endosom
acid
ph
activ
cystein
proteas
jaum
et
al
unfortun
clinic
studi
investig
ade
sarscov
patient
limit
sever
studi
report
correl
clinic
outcom
antisarscov
antibodi
affect
individu
taylor
et
al
contrari
studi
correl
poor
prognosi
earli
sarscov
seroconvers
ho
et
al
like
stori
virus
vaccineinduc
diseas
enhanc
also
concern
develop
sarscov
vaccin
report
small
subset
sarscov
vaccin
studi
de
wit
et
al
mous
studi
investig
role
sarscov
vaccin
induc
diseas
enhanc
tseng
et
al
reveal
vaccin
abl
protect
figur
gener
strategi
design
efficaci
vaccin
overcom
ade
requir
identifi
right
epitop
elicit
function
protect
antibodi
effect
vaccin
design
use
conserv
function
epitop
usual
exist
prefus
conform
surfac
glycoprotein
select
right
adjuv
direct
immun
system
toward
balanc
respons
car
accur
assess
efficaci
safeti
vaccin
differ
dose
preclin
clinic
trial
sarscov
infect
still
induc
direct
pulmonari
immunopatholog
suggest
hypersensit
sarscov
compon
anoth
studi
post
vaccin
challeng
mice
sarscov
nucleocapsid
protein
induc
sever
pneumonia
yasui
et
al
likewis
doubl
inactiv
sarscov
vaccin
mice
fail
provid
complet
protect
caus
enhanc
eosinophil
proinflammatori
pulmonari
respons
infect
boll
et
al
even
current
avail
data
support
correl
ade
sarscov
preexist
antibodi
studi
critic
need
accur
address
understand
issu
human
merscov
first
discov
human
sinc
case
fatal
report
worldwid
vaccin
approach
viru
also
target
spike
protein
vaccin
evalu
nonhuman
model
shown
reduc
lung
patholog
follow
challeng
merscov
nonetheless
like
coronavirus
vaccineinduc
diseas
enhanc
also
concern
merscov
vaccin
develop
merscov
preexist
antibodi
recent
shown
contribut
diseas
enhanc
recent
studi
houser
et
al
houser
et
al
research
use
new
zealand
white
rabbit
model
asymptomat
merscov
infect
evalu
role
primari
infect
protect
reinfect
result
show
rabbit
develop
nonneutr
antibodi
mer
viral
protein
nonprotect
also
induc
enhanc
pulmonari
inflamm
without
increas
viral
replic
moreov
passiv
transfer
serum
infect
rabbit
led
diseas
enhanc
investig
reveal
contribut
complement
protein
enhanc
patholog
specif
increas
protein
observ
protein
respons
releas
anaphylotoxin
recruit
immun
cell
lead
inflamm
houser
et
al
anoth
recent
studi
vaccin
transgen
mice
whole
inactiv
merscov
develop
eosinophil
infiltr
combin
enhanc
lung
diseas
merscov
challeng
agraw
et
al
despit
lack
evid
merscovinduc
ade
human
observ
anim
studi
highlight
risk
potenti
develop
enhanc
diseas
includ
sever
lung
patholog
individu
previous
infectedvaccin
merscov
presenc
nonneutr
crossreact
merscov
circul
human
coronavirus
could
contribut
mercovinduc
ade
yet
remain
unstudi
requir
investig
develop
test
coronavirus
vaccin
one
wide
studi
virus
context
ade
dengu
virus
denv
group
structur
relat
antigen
distinct
serotyp
name
diamond
pierson
infect
one
serotyp
produc
protect
typespecif
antibodi
crossreact
nonneutr
antibodi
subtyp
effici
enhanc
infect
halstead
halstead
et
al
first
report
enhanc
denv
infect
peripher
blood
mononuclear
cell
pbmc
cultur
obtain
immun
nonhuman
primat
nhp
compar
nonimmun
one
halstead
et
al
observ
attribut
presenc
nonneutr
antibodi
facilit
viral
infect
mononuclear
phagocyt
halstead
et
al
halstead
orourk
later
subsequ
studi
reveal
crossreact
antibodi
differ
denv
serotyp
predispos
factor
enhanc
ill
moren
et
al
denv
specif
ade
found
correl
increas
viremia
rate
vaughn
et
al
contribut
develop
sever
form
diseas
includ
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
guzman
et
al
epidemiolog
report
show
individu
preexist
dengu
immun
increas
risk
develop
dhf
requir
hospit
odd
ratio
greater
burk
et
al
moreov
infant
passiveacquir
immun
denv
immun
mother
tend
develop
sever
dhf
follow
primari
denv
infect
halstead
et
al
simmon
et
al
addit
secondari
heterotyp
infect
strongli
associ
high
viral
load
sever
diseas
endi
et
al
mani
virus
fcrmediat
antibodydepend
enhanc
main
mechan
dengu
enhanc
diseas
takada
kawaoka
mechan
proven
differ
model
experi
vivo
vitro
exampl
use
bhk
cell
show
sera
patient
secondari
infect
produc
higher
viru
titer
compar
cell
sera
primari
infect
moi
et
al
complement
receptor
cr
also
shown
play
role
denv
enhanc
ill
mechan
first
describ
cardosa
et
al
earli
anoth
flaviviru
west
nile
viru
wnv
enhanc
mediat
igmdepend
manner
cardosa
et
al
notabl
cr
mechan
enhanc
suggest
infect
spread
nonimmun
cell
well
sinc
cr
wide
distribut
mani
cell
exclus
restrict
immun
cell
like
takada
kawaoka
case
denv
complic
due
circul
four
antigen
crossreact
serotyp
also
due
divers
within
genotyp
gener
quasispeci
dengu
infect
may
affect
humor
respons
progress
diseas
secondari
infect
kurosu
taylor
et
al
natur
occur
denv
infect
produc
antibodi
crossreact
poorli
neutral
serotypespecif
highli
neutral
antibodi
repres
small
fraction
fibriansah
et
al
similar
natur
infect
denv
live
attenu
vaccin
gener
crossreact
nonneutr
antibodi
lead
enhanc
diseas
taylor
et
al
accordingli
structuralbas
design
chimer
denv
vaccin
induc
crossprotect
neutral
antibodi
respons
evalu
first
licens
denv
vaccin
cydtdv
tetraval
liveattenu
vaccin
design
chimera
yellow
fever
four
denv
halstead
vaccin
first
licens
mexico
use
countri
howev
complet
phase
clinic
evalu
vaccin
show
caus
advers
effect
certain
circumst
result
hospit
accordingli
recommend
made
manufactur
vaccin
seroposit
individu
age
year
endem
area
consid
enhanc
diseas
occur
vaccin
seroneg
individu
glycoprotein
shell
denv
consist
envelop
e
membran
protein
differ
conform
prematur
matur
viru
confer
uniqu
structur
form
perera
kuhn
immatur
viru
particl
precursor
membran
prm
e
protein
form
heterodim
make
trimer
spike
matur
furin
cleavag
releas
ntermin
contain
pr
peptid
prm
protein
leav
transmembran
protein
proteolyt
product
pr
peptid
associ
e
protein
found
homodim
virion
surfac
hanley
weaver
e
protein
compos
three
domain
e
domain
iiii
edi
edii
ediii
respons
bind
cellular
receptor
mediat
viru
fusion
entri
kuhn
et
al
roehrig
shown
antibodi
e
protein
major
compon
denv
neutral
humor
respons
pierson
serotypespecif
monoclon
neutral
antibodi
e
protein
also
isol
shrestha
et
al
sever
studi
character
neutral
epitop
e
protein
structur
differ
epitop
e
protein
recogn
antibodi
pierson
suggest
epitop
domain
ii
fusion
loop
diifl
conserv
elicit
crossreact
neutral
antibodi
differ
denv
flavivirus
well
matsui
et
al
pierson
shrestha
et
al
recent
studi
howev
show
antibodi
often
exhibit
low
moder
neutral
activ
might
result
enhanc
ill
smith
et
al
contrast
one
mab
recogn
bc
loop
domain
ii
adjac
fusion
loop
amino
acid
found
better
neutral
crossreact
four
serotyp
smith
et
al
sever
neutral
human
mab
isol
form
denv
patient
notabl
mab
recogn
di
ii
howev
antibodi
conformationdepend
sasaki
et
al
recent
found
unlik
mousegener
neutral
mab
immun
recombin
e
protein
human
neutral
mab
bind
intact
virion
purifi
recombin
protein
gallichott
et
al
suggest
human
neutral
antibodi
gener
complex
quaternari
structur
assembl
virion
explain
uniqu
arrang
e
protein
lie
flat
surfac
bound
antibodi
structur
rearrang
viral
fusion
prevent
fibriansah
et
al
quaternari
structuredepend
antibodi
commonli
isol
de
alwi
et
al
serospecif
human
mab
target
diii
region
e
protein
teoh
et
al
fibriansah
et
al
anoth
highli
potent
human
mab
identifi
bind
three
function
e
protein
domain
time
consid
promis
target
novel
vaccin
design
fibriansah
et
al
use
antibodydeplet
techniqu
remov
serotyp
crossreact
antibodi
elimin
enhanc
heterotyp
serotyp
enhanc
homotyp
serotyp
affect
indic
homotyp
enhanc
occur
typespecif
antibodi
present
low
concentr
analysi
deplet
e
antibodi
use
recombin
e
protein
result
partial
decreas
denv
enhanc
ill
indic
anti
antibodi
partial
respons
denv
ade
de
alwi
et
al
moreov
competit
studi
use
prmspecif
fab
fragment
reveal
e
prmspecif
antibodi
might
caus
mediat
ade
although
antiprm
antibodi
constitut
major
compon
antidenv
humor
respons
highli
crossreact
low
neutral
potenc
even
high
concentr
thu
promot
mediat
ade
dejnirattisai
et
al
cell
infect
denv
releas
high
quantiti
immatur
prmcontain
virion
due
unsuccess
prm
cleavag
provok
gener
prm
antibodi
antibodi
found
elev
patient
secondari
infect
lai
et
al
although
immatur
virion
noninfecti
restor
infect
interact
prm
antibodi
turn
facilit
bind
entri
bear
cell
rodenhuiszybert
et
al
interestingli
antiprm
antibodi
also
shown
recogn
cryptic
didii
junction
e
protein
chan
et
al
although
site
unavail
function
fold
e
protein
caus
problem
design
e
protein
subunitbas
vaccin
taylor
et
al
addit
crossreact
nonneutr
enhanc
antibodi
map
amino
acid
correspond
residu
prm
protein
luo
et
al
consequ
prm
antibodi
contribut
significantli
enhanc
infect
henc
care
evalu
design
denv
vaccin
structur
studi
enabl
better
understand
virusantibodi
interact
impact
induc
protect
enhanc
ill
crystal
structur
fab
complex
highli
conserv
ab
loop
diii
e
protein
poorli
access
matur
virion
show
variabl
neutral
activ
three
denv
serotyp
emphas
role
conform
chang
neutral
even
conserv
epitop
midgley
et
al
therefor
possibl
enhanc
antibodi
capabl
recogn
hidden
epitop
undergo
conform
chang
allow
antibodi
bind
lead
ade
taylor
et
al
structur
studi
concern
enhanc
epitop
definit
sharpen
knowledg
ade
denv
importantli
denv
studi
base
serolog
find
wherea
cellular
respons
remain
less
studi
recent
studi
priyamvada
et
al
shown
secondari
denv
infect
plasmablast
secret
high
affin
crossreact
e
specif
antibodi
exhibit
viru
neutral
vitro
rather
bind
recombin
envelop
protein
highlight
import
viriondepend
b
cell
interact
limit
envelop
protein
bind
assay
priyamvada
et
al
research
includ
epitopemap
experi
compar
studi
plasmablast
primari
secondari
denv
infect
need
better
character
antidenv
broadli
neutral
antibodi
address
role
plasmablast
denv
crossreact
serotyp
specif
neutral
potenc
zika
viru
zikv
reemerg
mosquitotransmit
flaviviru
first
discov
uganda
remain
restrict
part
africa
asia
caus
major
outbreak
brazil
rapidli
spread
american
countri
endem
sever
us
territori
given
wide
spread
associ
neurolog
disord
guillainbarr
syndrom
adult
microcephali
newborn
zikv
rais
seriou
public
health
concern
worldwid
member
flavivirus
zikv
share
consider
degre
structur
similar
virus
genu
includ
denv
wnv
hasan
et
al
moreov
zikv
circul
mani
denv
wnv
endem
area
million
peopl
preexist
flavivirus
immun
bardina
et
al
yellow
fever
vaccin
also
administ
area
zika
circul
central
america
highlight
possibl
role
ade
zika
viru
pathogenesi
mani
recent
studi
focus
studi
immunolog
crossreact
zikv
flavivirus
potenti
effect
zikv
pathogenesi
enhanc
ill
vitro
studi
use
sera
denv
seroposit
individu
demonstr
abil
denv
antibodi
enhanc
zikv
infect
sever
mab
deriv
denvspecif
plasmablast
shown
crossreact
zikv
also
neutral
viru
sera
mab
denv
immun
patient
result
enhanc
zika
infect
receptor
bear
cell
priyamvada
et
al
antibodi
linear
denv
epitop
fusion
loop
e
protein
also
abl
drive
zikv
enhanc
abl
bind
neutral
viru
dejnirattisai
et
al
moreov
crossreact
antibodi
direct
edi
edii
elicit
denv
zikv
infect
show
poor
neutral
potent
enhanc
zikv
denv
cell
cultur
lethal
enhanc
denv
diseas
mice
stettler
et
al
nevertheless
vitro
serolog
find
accur
reflect
actual
risk
diseas
enhanc
hypothesi
ade
zikv
anoth
flaviviru
infect
examin
vivo
zikv
enhanc
observ
mice
receiv
human
seroposit
sera
denv
wnv
bardina
et
al
evidenc
increas
mortal
morbid
viremia
enhanc
mediat
igg
engag
receptor
howev
result
studi
show
also
protect
effect
crossreact
flaviviru
antibodi
present
suffici
concentr
emphas
variabl
effect
crossreact
flavivirus
antibodi
protect
enhanc
diseas
depend
titer
surround
physiolog
condit
studi
also
highlight
possibl
role
preexist
wnv
immun
zikv
ade
structur
relat
flaviviru
cocircul
zikv
mani
region
around
globe
anoth
recent
report
prior
exposur
zikv
also
found
significantli
enhanc
denv
infect
rhesu
macaqu
georg
et
al
contrast
swanstrom
et
al
demonstr
human
mab
denv
infect
patient
neutral
zikv
cell
cultur
mediat
protect
murin
model
swanstrom
et
al
pantoja
et
al
also
report
denvmedi
enhanc
zikv
infect
rhesu
macaqu
although
result
confirm
ade
vitro
zikv
enhanc
denv
immun
anim
vivo
rather
found
previou
exposur
denv
result
reduc
zikv
viremia
rate
compar
denv
macaqu
pantoja
et
al
hand
studi
mice
indic
zikv
infect
confer
protect
wnv
challeng
et
al
discrep
differ
studi
term
diseas
enhanc
protect
attribut
multipl
factor
includ
type
titer
evalu
antibodi
strain
use
infect
use
anim
model
instanc
denv
infect
model
known
develop
sever
neurolog
complic
case
human
zompi
harri
pantoja
et
al
sever
report
character
humor
respons
zikv
correl
preexist
flaviviru
immun
epitop
target
cell
overal
cellular
respons
less
studi
found
memori
cell
produc
denv
infect
vaccin
recogn
zikv
conserv
epitop
lead
stronger
faster
cell
respons
grifoni
et
al
interstingli
cell
respons
zikv
target
mainli
structur
protein
mainli
direct
nonstructur
protein
denv
infect
grifoni
et
al
final
use
trnsgenic
mice
reveal
zikvspecif
zikvdenv
crossreact
epitop
elicit
adequ
cell
respons
decreas
level
zikv
infect
wen
et
al
wnv
anoth
flaviviru
link
ade
sinc
hawk
viru
three
structur
protein
capsid
c
premembranemembran
prmm
envelop
e
seven
nonstructur
protein
colpitt
et
al
human
wnv
infect
caus
subclin
febril
ill
case
lead
lethal
enceph
patient
whether
relat
ade
still
fulli
known
taylor
et
al
similar
denv
diseas
enhanc
main
caus
ade
wnv
infect
relat
presenc
subneutr
concentr
antibodi
bind
virion
facilit
entri
cell
bear
receptor
pierson
et
al
addit
antibodi
titer
protect
diseas
enhanc
wnv
mab
depend
class
isotyp
antibodi
cardosa
et
al
complementmedi
ade
also
report
wnv
infect
one
studi
viral
infect
fcrbear
cell
enhanc
presenc
antivir
monoclon
igm
antibodi
enhanc
block
anticompl
receptor
type
antibodi
antibodi
specif
fcr
cardosa
et
al
flavivirus
e
glycoprotein
primari
target
neutral
immun
respons
colombag
et
al
previous
describ
denv
domain
ii
e
protein
encompass
epitop
near
fusion
loop
elicit
crossreact
subneutr
antibodi
thu
enhanc
risk
ade
oliph
et
al
hand
potent
neutral
antibodi
respons
wnv
infect
mice
direct
domain
iii
e
protein
pierson
et
al
strong
neutral
potenc
demonstr
antibodi
bind
diii
region
e
protein
antibodi
isol
wnv
infect
patient
vogt
et
al
epitop
region
exclus
found
intact
virion
recombin
e
protein
compos
amino
acid
residu
interact
monom
e
dimer
hing
region
edi
edii
brandler
tangi
antibodi
epitop
found
neutral
wnv
infect
neutral
viru
postattach
step
thu
prevent
rearrang
e
protein
fusionact
state
requir
phinduc
infect
host
cell
kaufmann
et
al
ade
also
report
sever
human
anim
virus
alphaviru
subfamili
suggest
earli
subneutr
titer
semliki
forest
sindbi
virus
sinv
could
lead
antibodi
depend
plaqu
enhanc
infect
macrophag
chana
et
al
peiri
porterfield
recent
ade
report
chikungunya
viru
chikv
presenc
low
igg
titer
elicit
singl
immun
chikv
vaccin
et
al
studi
ross
river
viru
rrv
also
shown
persist
product
infect
macrophag
use
dilut
sera
rrv
infect
patient
linn
et
al
main
event
alphavir
diseas
enhanc
involv
macrophag
highli
permiss
alphavirus
infect
suscept
persist
viru
product
lidburi
et
al
ade
also
record
ebola
viru
ebov
infect
ebov
belong
filovirida
famili
caus
agent
ebola
hemorrhag
fever
rare
deadli
diseas
burk
et
al
largest
ebola
outbreak
occur
recent
west
africa
affect
around
individu
result
death
massiv
outbreak
prompt
intens
effort
develop
treatment
vaccin
diseas
enhanc
ebov
antibodi
rais
concern
advers
vaccin
effect
sever
earli
report
show
immun
mice
surfac
glycoprotein
gp
zair
strain
ebola
zebov
induc
enhanc
infect
vesicular
stomat
viru
vsv
pseudotyp
protein
vitro
enhanc
activ
shown
occur
fcrmediat
mechan
takada
et
al
addit
ebov
enhanc
infect
nonmonocytot
cell
found
occur
differ
mechan
requir
involv
complement
factor
case
two
igg
molecul
bind
specif
epitop
close
proxim
permit
bind
fc
portion
antibodi
result
complex
format
enhanc
viruscel
interact
takada
kawaoka
subsequ
studi
show
ade
ebov
gp
strain
specif
correl
igm
class
antibodi
low
affin
takada
et
al
recent
work
furuyama
et
al
investig
molecular
mechan
ebov
ade
highlight
involv
scr
famili
protein
tyrosin
kinas
ptk
iia
mediat
ade
furuyama
et
al
found
antibodyviru
complex
bind
cell
surfac
trigger
src
signal
pathway
turn
contribut
facilit
viral
entri
human
leukemia
cell
addit
specif
epitop
zebov
gp
found
enhanc
infect
confirm
use
mous
antisera
chimer
zebov
gp
lack
ade
epitop
less
ade
activ
produc
compar
mous
antisera
wildtyp
zebov
gp
takada
et
al
although
mab
zebov
gp
shown
protect
effect
lethal
infect
mice
qiu
et
al
enhanc
viru
infect
gener
antigp
antibodi
rais
concern
use
protein
vaccin
candid
taylor
et
al
recent
studi
investig
abil
mab
obtain
filoviru
human
survivor
induc
ade
kuzmina
et
al
result
show
subneutr
concentr
mab
potenti
ade
regardless
particular
epitop
specif
neutral
capac
subclass
moreov
receptor
block
fc
domain
mutat
reduc
yet
abolish
ade
observ
highaffin
bind
antibodi
nevertheless
lowaffin
bind
antibodi
still
abl
caus
ade
explain
previou
failur
ebov
therapeut
attempt
insuffici
dose
passiv
transfer
antibodi
administ
kuzmina
et
al
hand
use
high
concentr
monoclon
polyclon
antibodi
show
improv
efficaci
absenc
ade
anim
model
human
volunt
kudoyarovazubavichen
et
al
corti
et
al
current
approv
vaccin
ebov
although
mani
promis
vaccin
candid
clinic
trial
includ
vectorbas
vaccin
replic
vesicular
stomat
viru
rvsv
replicationdefect
chimpanze
adenoviru
dna
vaccin
subunit
vaccin
ohimain
pavot
importantli
light
previous
observ
ebov
ade
complex
process
affect
differ
immun
strategi
may
lead
extrem
virul
caution
taken
design
develop
new
ebola
vaccin
addit
vaccin
must
care
test
wide
dose
rang
order
defin
protect
dose
overcom
ade
similar
ebola
viru
complementmedi
ade
report
human
immunodefici
viru
hiv
infect
observ
hiv
seroposit
sera
typic
low
neutral
activ
abil
enhanc
viru
infect
cell
cultur
robinson
et
al
specif
human
monoclon
antibodi
direct
transmembran
glycoprotein
enhanc
infect
vitro
robinson
et
al
document
complement
receptor
bear
cell
suscept
enhanc
infect
hiv
seroposit
sera
conclud
essenti
hiv
complement
depend
enhanc
robinson
et
al
hand
fcr
depend
enhanc
observ
macrophag
cell
specif
mediat
fcriii
homsi
et
al
entri
hiv
cell
mediat
conform
chang
occur
interact
hiv
envelop
protein
chemokin
receptor
cell
surfac
induc
addit
conform
chang
facilit
fusion
cell
membran
entri
viral
capsid
target
cell
guillon
et
al
therefor
independ
neutral
capabl
antibodi
hiv
enhanc
infect
produc
conform
chang
shmelkov
et
al
although
idea
hiv
ade
propos
decad
ago
shortli
first
isol
viru
ignor
hiv
research
long
time
enhanc
ill
observ
hiv
clinic
trial
shmelkov
et
al
enhanc
diseas
report
hiv
vaccin
clinic
trial
attribut
nonneutr
envelopespecif
plasma
iga
antibodi
hayn
et
al
moreov
evalu
aidsvax
vaccin
genentech
us
show
diseas
enhanc
well
statist
analysi
aidsvax
clinic
trial
indic
low
antibodi
respons
recombin
glycoprotein
increas
rate
hiv
infect
compar
control
group
gilbert
et
al
shmelkov
et
al
signific
effort
made
identifi
tand
bcell
protect
enhanc
epitop
hiv
broadli
neutral
antibodi
bnab
produc
low
number
infect
individu
typic
target
conform
epitop
mask
glycosyl
well
expos
immun
system
contrast
epitop
target
cell
short
peptid
use
design
vaccin
free
nonprotect
epitop
fischer
et
al
mccoy
burton
accordingli
effect
hiv
vaccin
design
contain
conserv
cell
epitop
well
select
b
cell
epitop
capabl
strictli
elicit
bnab
antibodydepend
cellular
cytotox
adcc
antibodydepend
cellmedi
viru
inhibit
adcvi
rather
harm
antibodi
respons
sahay
et
al
report
also
reveal
ade
herpesvirus
includ
epsteinbarr
viru
herp
simplex
viru
footandmouth
diseas
viru
baxt
mason
measl
viru
huisman
et
al
rabi
viru
porterfield
sever
other
de
swart
et
al
antibodi
enhanc
epitop
also
describ
number
virus
exampl
mab
hepat
c
viru
glycoprotein
elicit
week
immun
meyer
et
al
well
mab
nucleocapsid
n
glycoprotein
porcin
reproduct
respiratori
syndrom
prr
viru
canceltirado
et
al
tabl
summar
ade
observ
differ
viral
infect
recent
studi
shed
light
viralinduc
ade
molecular
level
despit
limit
progress
addit
viral
host
genet
factor
intracellular
signal
found
play
crucial
role
ade
pathogenesi
modul
cell
signal
ade
remark
effect
consid
impact
differ
defens
pathway
classic
ade
occur
two
distinct
mechan
intrins
extrins
pathway
taylor
et
al
extrins
ade
involv
facilit
viru
entri
infect
cell
discuss
earlier
review
mechan
mediat
enhanc
antibodi
increas
viru
uptak
fcreceptor
complement
receptor
hand
intrins
ade
mechan
innat
adapt
intracellular
antivir
respons
alter
lead
increas
viru
product
consequ
high
viral
load
flips
et
al
favor
environ
viru
surviv
attain
suppress
essenti
antivir
gene
express
thoma
et
al
particularli
found
ade
diminish
antivir
respons
transcript
level
mechanist
studi
shown
ade
affect
lipopolysaccharid
lp
induc
antivir
activ
macrophag
specif
target
transcript
translat
essenti
antivir
factor
result
uncontrol
viral
replic
lidburi
mahalingam
instanc
analysi
rrvinfect
macrophag
rna
level
show
enhanc
infect
associ
disrupt
antivir
transcript
factor
complex
tumor
necrosi
factor
alpha
tnfalpha
nitricoxid
synthas
ifn
regulatori
factor
well
increas
express
mahalingam
lidburi
also
suggest
downregul
inflammatori
cytokin
mahalingam
lidburi
lead
toward
increas
viral
replic
figur
observ
indic
alter
intracellular
signal
ade
suppress
immun
defens
gene
also
enhanc
express
host
gene
contribut
viru
surviv
thoma
et
al
moreov
recent
studi
high
throughput
sequenc
mirna
human
pbmc
follow
ade
infect
perform
jiang
sun
result
reveal
ade
associ
alter
mirna
express
profil
highlight
role
mirna
modul
immun
respons
nonetheless
futur
studi
absolut
need
describ
exact
role
mirna
ade
viral
induc
enhanc
diseas
also
influenc
sever
host
genet
factor
interestingli
studi
boonnak
et
al
show
singl
nucleotid
polymorph
snp
promot
region
affect
express
level
adeassoci
boonnak
et
al
individu
homozyg
gcc
haplotyp
present
highest
level
follow
acc
ata
haplotyp
studi
highlight
signific
genet
suscept
infecti
diseas
thu
import
identifi
host
genet
factor
includ
gene
polymorph
relat
innat
adapt
immun
respons
viral
infect
includ
limit
cellular
receptor
gene
mhc
cytokin
gen
well
complement
pathway
gene
ade
phenomenon
differ
viru
infect
still
area
intens
studi
especi
develop
new
vaccin
vaccin
fail
produc
broad
protect
antibodi
could
lead
advers
effect
render
vaccin
individu
suscept
infect
demonstr
previou
clinic
trial
success
vaccin
approach
reli
design
novel
immunogen
induc
balanc
protect
immun
suggest
efficaci
vaccin
strictli
target
protect
epitop
band
tcell
abl
elicit
function
immun
respons
bnab
adcc
adcvi
sahay
et
al
moreov
select
appropri
adjuv
affect
vaccin
immunogen
consider
thu
affect
vaccin
efficaci
nonetheless
even
select
appropri
antigen
adjuv
ade
remain
concern
neutral
antibodi
elicit
subneutr
dose
consequ
evalu
vaccin
term
protect
enhanc
dose
crucial
need
vaccin
administr
figur
viru
pathogenesi
host
immun
relationship
control
multipl
factor
ade
complex
disord
may
lead
extrem
virul
mani
virus
consid
involv
wide
number
virus
ade
variou
mechan
propos
explain
phenomenon
current
observ
suggest
ade
primarili
induc
nonneutr
antibodi
via
taylor
et
al
complement
depend
pathway
takada
kawaoka
cours
infect
differ
type
antibodi
produc
repres
mixtur
neutral
enhanc
nonneutr
antibodi
takada
et
al
viru
enhanc
neutral
depend
multipl
factor
includ
antibodi
type
class
antibodi
titer
strain
viru
well
presenc
certain
complement
molecul
surfac
protein
main
antigen
determin
antibodi
enhanc
respons
ha
influenza
ramakrishnan
et
al
g
protein
rsv
spike
protein
sar
kam
et
al
e
glycoprotein
flavivirus
bardina
et
al
transmembran
gp
hiv
robinson
et
al
gp
ebola
viru
takada
et
al
glycoprotein
hcv
meyer
et
al
numer
studi
character
host
factor
b
cellular
respons
viral
factor
target
epitop
respons
diseas
protectionenhanc
context
vaccin
design
import
ensur
vaccin
test
differ
dose
ensur
elicit
optim
titer
neutral
antibodi
better
understand
viralhost
interplay
context
enhanc
diseas
ill
would
greatli
improv
develop
highli
safe
effect
vaccin
therapeut
hy
ms
design
wrote
first
draft
manuscript
aa
proofread
revis
manuscript
qatar
nation
librari
fund
public
articl
